The safest type is CAR-T CD19, which is suitable for B cell leukemia, as well as for B cell lymphoma. Other CAR-T that are currently being developed for use in hematologic malignancies include anti-CD20, CD22, ROR1, CD33, CD8, CD123, CD56, CD38, CD138, and BCMA. For solid tumors, it is present mesothelin, GD2, ROR1, CD56, Her2, EGFRviii, PSMA, CD44v6.